+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Biopharmaceutical Excipients Market Report is set to have rapid growth due Presence of diversified suppliers and strong research funding in chemicals division at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopharmaceutical Excipients Market Forecast 2019-2029 : By Product (Solubilizers & Surfactants/Emulsifiers, Specialty Excipients, Polyols, Carbohydrates), By Region, And Segment Forecasts.

The global Biopharmaceutical Excipients market is poised for rapid growth between 2019 and 2029. Factors such as the growing pharmaceutical industry combined with advances in functional excipients, the growing adoption of orphan drugs and the increasing uptake of biopharmaceuticals are driving the market for pharmaceutical excipients.

Some recent advancements include:

  • On December 2018, Roquette Feres (France) signed an agreement with Thermo Fisher Scientific (USA), which gives Thermo Fisher the right to distribute Roquette's product portfolio in the United States and Canada.
  • On January 2019, Croda International (United Kingdom) acquired Brenntag Biosector (Denmark) for its portfolio of vaccine adjuvants that would complement Croda's portfolio of pharmaceutical excipients.
  • On April 2019, Colorcon, Inc. (United States) signed an agreement with DuPont Nutrition and Biosciences (United States) to improve the current portfolio of CR Alliance products.
  • Onn February 2019, Associated British Foods plc (United Kingdom) signed an agreement with Indchem International (India) on the basis of which Indchem will distribute the functional lipid excipient product line of the Associated British Food on the Indian market.

Leading companies featured in the report include ABITEC Corp.; Signet Chemical Corporation Pvt. Ltd.; Roquette; Sigachi Industries Pvt. Ltd.; Meggle AG; Colorcon, Inc.; DFE Pharma; Clariant; IMCD; SPI Pharma; Pharmonix Biological Pvt. Ltd.; Spectrum Chemical Manufacturing Corp., and BASF SE

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read